City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  115  Clinical trial(s) found  (Page 1 of 5 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 17509 ClinicalTrials.gov Number: NCT03439280

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenecity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma

COH Protocol Number: 17505 ClinicalTrials.gov Number: NCT03494569

Principal Investigator: Monzr Al malki, MD
Sponsor: Institutional

Title:  Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) Combined with Fludarabine and Melphalan as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome

COH Protocol Number: 17502 ClinicalTrials.gov Number: NCT03422627

Principal Investigator: Amandeep Salhotra, MD
Sponsor: Industrial

Title:  A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 592 in Adult Subjects With Steroid Refractory Chronic Graft versus Host Disease

COH Protocol Number: 17468 ClinicalTrials.gov Number: NCT03438318

Principal Investigator: Erminia Massarelli, MD, PhD
Sponsor: Industrial

Title:  A Multicenter, Two-Part, Phase 1b Clinical Study Of CMP-001 in Combination with Atezolizumab With and Without Radiation Therapy in Subjects with Advanced Non Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 17454 ClinicalTrials.gov Number: NCT03394755

Principal Investigator: Vinod Pullarkat, MD
Sponsor: Industrial

Title:  A Phase I, Multi-Center, Open-Label, Dose Escalation Study of Thrombosomes® in Bleeding Thrombocytopenic Patients in Three Cohorts

COH Protocol Number: 17450 ClinicalTrials.gov Number: NCT03008278

Principal Investigator: Joseph Chao, MD
Sponsor: NCI Approved External Peer Review

Title:  PHII-162, NCI#10066: A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)

COH Protocol Number: 17434 ClinicalTrials.gov Number: NCT03399799

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64407564, a Humanized GPRC5D x CD3 DuoBody® Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

COH Protocol Number: 17429 ClinicalTrials.gov Number: NCT03239392

Principal Investigator: Christiane Querfeld, MD, PhD
Sponsor: Industrial

Title:  A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients with Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma

COH Protocol Number: 17428 ClinicalTrials.gov Number: NCT03440567

Principal Investigator: Robert Chen, MD
Sponsor: Institutional

Title:  A Phase I Study of Avelumab plus Utomilumab-based Combination Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

COH Protocol Number: 17418 ClinicalTrials.gov Number: NCT03181126

Principal Investigator: Vinod Pullarkat, MD
Sponsor: Industrial

Title:  A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination with Navitoclax and Chemotherapy in Subjects with Relapsed Acute Lymphoblastic Leukemia

COH Protocol Number: 17405 ClinicalTrials.gov Number: NCT03430011

Principal Investigator: Myo Htut, MD
Sponsor: Industrial

Title:  Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory Multiple Myeloma

COH Protocol Number: 17389 ClinicalTrials.gov Number: NCT02180711

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination with Rituximab in Subjects with Indolent B-cell Non-Hodgkin Lymphoma

COH Protocol Number: 17379 ClinicalTrials.gov Number: NCT03411915

Principal Investigator: Warren Chow, MD
Sponsor: Industrial

Title:  A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects with Advanced Neuroendocrine and Gastrointestinal Stromal Tumors

COH Protocol Number: 17365 ClinicalTrials.gov Number: NCT03374085

Principal Investigator: Chatchada Karanes, MD
Sponsor: Industrial

Title:  A Phase 1 Multicenter, Open-Label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

COH Protocol Number: 17352 ClinicalTrials.gov Number: NCT03374254

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab (MK-3475) Plus Binimetinib Alone or the Combination of Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Participants with Metastatic Colorectal Cancer (KEYNOTE-651)

COH Protocol Number: 17345 ClinicalTrials.gov Number: NCT03199586

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  First-in-Human, Dose Finding, Open Label Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients with Advanced or Metastatic Solid Tumors (including Lymphoma)

COH Protocol Number: 17340 ClinicalTrials.gov Number: NCT03319940

Principal Investigator: Ravi Salgia, MD
Sponsor: Industrial

Title:  A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer

COH Protocol Number: 17332 ClinicalTrials.gov Number: NCT03355066

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with Advanced Solid Tumors

COH Protocol Number: 17293 ClinicalTrials.gov Number: NCT03035253

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1b Study of Navicixizumab (OMP-305B83) Plus FOLFIRI as Second Line Therapy in Subjects with Metastatic Colorectal Cancer

COH Protocol Number: 17273 ClinicalTrials.gov Number: NCT03331198

Principal Investigator: Tanya Siddiqi, MD
Sponsor: Industrial

Title:  An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

COH Protocol Number: 17270 ClinicalTrials.gov Number: NCT03157128

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

COH Protocol Number: 17228 ClinicalTrials.gov Number: NCT02675452

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia

COH Protocol Number: 17227 ClinicalTrials.gov Number: NCT03224819

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 673 Administered as Short Term Intravenous Infusions in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

COH Protocol Number: 17217 ClinicalTrials.gov Number: NCT03248479

Principal Investigator: Guido Marcucci, MD
Sponsor: Industrial

Title:  A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Hematological Malignancies

COH Protocol Number: 17212 ClinicalTrials.gov Number: NCT03317119

Principal Investigator: Marwan Fakih, MD
Sponsor: Institutional

Title:  A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-resistant RAS-mutated (PIK3CA/PTEN-wild-type) Metastatic Colorectal Cancer

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.